Our Science

OUR SCIENCE

Humanizing the treatment of cancer

We are driven by the desire to make treatment more humane through reducing the side effects and optimizing the potency of cancer treatment

We are driven by the desire to make treatment more humane through reducing the side effects and optimizing the potency of cancer treatment

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Publication by Dr. Christine Lovly (Vanderbilt University) about the potency of ensartinib (X-396) against cancers driven by ALK mutations.

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

Publication by Dr. Di Paolo and colleagues highlighting ensartinib’s activity in mutant ALK-driven tumor models.

eXalt3: A phase 3 study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Phase 3 data presented by Dr. Leora Horn at the 2017 European Lung Cancer Conference in Geneva, Switzerland, May 5-8, 2017.

Response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients with ALK+ NSCLC

Ensartinib phase I/II response data presented by Dr. Leora Horn at the IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016.

Phase I/II trial of ensartinib+(X-396) in patients with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy

Poster presented by Dr. Leora Horn at the 2016 ESMO Congress in Copenhagen, Denmark, October 7-11, 2016. This presentation highlighted data from the ensartinib phase I/II trial.

Phase I/II trial of ensartinib (X-396), a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

Ensartinib phase I/II current results and response data presented by Dr. Ticiana Leal at the IASLC 7th Latin American Conference on Lung Cancer, August 25-27, 2016 in Panama City, Panama.

Plasma genotyping of patients in the eXalt2 trial: ensartinib (X-396) in ALK+ non-small cell lung cancer (NSCLC)

Presentation from the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting, presented by Dr. Leora Horn on ensartinib phase I/II data.